This company launches Covid-19 drug at Rs 103 per tablet
A drug firm Glenmark Pharmaceuticals stated that it has launched antiviral drug Favipiravir, under the brand name FabiFlu, which will be used for the treatment of patients with mild to moderate Covid-19. The antiviral drug costs at a price of about Rs 103 per tablet.
A 200 mg tablet will be available at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, the Glenmark Pharmaceuticals said. Reportedly, FabiFlu is the first oral favipiravir-approved medicine in India for the treatment of Covid-19.
Meanwhile, medicine can't be taken without a prescription. The drug firm also said that Glenmark will be able to provide the antiviral drug for about 82,500 patients in the first month. "We will be monitoring the evolving situation closely and on the basis of the situation, we scale up and meet the healthcare needs of the country, Glenmark Pharmaceuticals stated.
The firm is producing active pharmaceutical ingredients (API) at its Ankleshwar plant, while the formulation of FabiFlu is being manufactured at its Baddi plant. The drug will be available through hospitals as well as the retail channel.
Also Read | ‘Don’t threaten doctors and health workers, support them,’: Supreme Court to Delhi government
Favipiravir is said to be a generic version of Avigan of Fujifilm Toyama Chemical, Japan, a subsidiary of Fujifilm Corporation. Reportedly, it showed encouraging results in patients with mild to moderate Covid-19.
-PTC News
